

Comparison of the activities of wild type and mutant enhancing factor/mouse secretory phospholipase A₂ proteins

BHAKTI M KIRTANE and RITA MULHERKAR*

Laboratory of Genetic Engineering, Cancer Research Institute, Tata Memorial Centre, Parel, Mumbai 400 012, India

*Corresponding author (Fax, 91-22-4146089; Email, ritam@vsnl.com)

Enhancing factor (EF) protein, an isoform of secretory phospholipase A₂ (PLA₂), was purified as a modulator of epidermal growth factor from the small intestine of the Balb/c mouse. It was for the first time that a growth modulatory property of sPLA₂ was demonstrated. Deletion mutation analysis of EF cDNA carried out in our laboratory showed that enhancing activity and phospholipase activity are two separate activities that reside in the same molecule. In order to study the specific amino acids involved in each of these activities, two site-directed mutants of EF were made and expressed *in vitro*. Comparison of enhancing activity as well as phospholipase A₂ activity of these mutant proteins with that of wild type protein helped in identification of some of the residues important for both the activities.

[Kirtane B M and Mulherkar R 2002 Comparison of the activities of wild type and mutant enhancing factor/mouse secretory phospholipase A₂ proteins; *J. Biosci.* 27 489494]

1. Introduction

Enhancing factor (EF), a mouse homologue of secretory phospholipase A₂ (sPLA₂), is a dual function molecule. It shows enhancing activity i.e. it enhances the binding of epidermal growth factor (EGF) to A431 cells in a radio-receptor assay (Deo *et al* 1983) and it also shows phospholipase activity (Mulherkar *et al* 1993). EF is a 146 amino acid protein with a 21 amino acid long signal peptide. A 100 kDa cell membrane receptor for EF has been demonstrated on A431 cells (Mulherkar and Deo 1986). EF along with EGF induces anchorage independent growth of normal rat kidney fibroblasts (Mulherkar and Deo 1986). Studies with heparin and heparitinase in the radio-receptor assay suggested that EF is a heparin binding protein and enhancing activity is inhibited in the presence of heparin (Wagle *et al* 1997). It was, therefore, proposed that EF is a unique molecule that binds itself to the cell membrane, through its own receptor and in turn, provides a binding site for EGF. Immunohistochemical studies have demonstrated that EF is localized in the Pa-

neth cells of the small intestine as well as to the hair follicles of new born mice (Desai *et al* 1991; Mulherkar *et al* 1991).

Secretory phospholipase A₂ (sPLA₂) is a highly conserved family of enzymes that has molecular masses of about 14 kDa and requires Ca²⁺ for the catalytic activity (Murakami *et al* 1997). The Ca²⁺ binding loop has a typical glycine-rich sequence and presence of aspartic acid at amino acid 49. The active site of the enzyme shows the presence of highly conserved residues of His⁴⁸, Tyr⁵², Tyr⁷³ and Asp⁹⁹. Apart from phospholipid digestion, sPLA₂ has the potential to mediate a wide range of biological activities which include mediators of inflammation, eicosanoid generation, antibacterial activity and initiator of cell proliferation. Interestingly, some of these activities of sPLA₂ are independent of its catalytic activity. Lys-49, a variant of snake venom type II PLA₂ that is unable to hydrolyze phospholipids, shows cytolytic activity (Francis *et al* 1991). Some of the receptor-mediated functions of sPLA₂ are also independent of its catalytic activity. For example sPLA₂ receptor mediated

Keywords. Enhancing factor; epidermal growth factor; heparin binding; phospholipase A₂; site-directed mutagenesis

Abbreviations used: EF, Enhancing factor; EGF, epidermal growth factor; sPLA₂, secretory phospholipase A₂.

activation of cPLA₂ has been demonstrated in murine bone marrow-derived mast cells and a noncatalytic ligand of this receptor also induced an increase in cPLA₂ activity (Fonteh *et al* 2000). sPLA₂ induced secretion of *b*-glucuronidase and IL-6 by human macrophages is also thought to be independent of the enzymatic activity (Triggiani *et al* 2000). Our laboratory has reported for the first time the growth modulatory property of mouse sPLA₂/EF (Mulherkar and Deo 1986). Deletion mutation studies carried out in our laboratory have shown that enhancing activity and phospholipase activity are two separate activities residing in a single molecule (Kadam and Mulherkar 1999). One of the deletion mutants having only the first 82 amino acids showed enhancing activity but no phospholipase activity. This suggested that enhancing activity does not depend on phospholipase activity. In the present study site-directed mutagenesis of EF/mouse sPLA₂ was carried out in order to mutate specific amino acid residues without altering the size of the molecule. The effect of these mutations on both the activities of the molecule was studied by expressing it in 293 cells.

2. Materials and methods

2.1 Site-directed mutagenesis of EF

Two separate primers were designed to carry out mutations at two separate sites. One of the primers (GE1-5' P-CTG TGT TAC TCA GAA ATG TTG CTA CAA GA 3') would change His⁴⁸ and Asp⁴⁹ (amino acid positions according to aligned PLA₂ sequences) to Gln⁴⁸ and Lys⁴⁹ respectively, while another primer (GE2-5' P-GGT GGG AGT TCT TGT TTT TCA GTA ACT T 3') was designed to change Tyr⁶⁷ and Tyr⁶⁹ to Asn⁶⁷ and Asn⁶⁹ respectively. 'GeneEditorTM *in vitro* site-directed mutagenesis system' (Promega) was used to carry out mutagenesis of EF cDNA. This system uses antibiotic selection to obtain high frequency of mutants. Plasmid pRcCMV-EF, where full length EF cDNA has been cloned under CMV promoter (Kadam and Mulherkar 1999), was used as template for mutagenesis reaction. The selection oligonucleotide was annealed to template DNA at the same time as a mutagenic oligonucleotide. Subsequent synthesis and ligation of a mutant strand linked the two oligonucleotides. BMH 71-18 *mutS*, which is a DNA repair minus strain of *Escherichia coli*, was used to avoid selection against the desired mutation. Plasmid DNA extracted from this culture was used for second round transformation into *E. coli* JM109, which ensures proper segregation of mutant and wild type plasmids. Mutant plasmid was identified by sequencing.

2.2 Sequencing

Double stranded plasmid DNA extracted by the miniprep protocol was quantitated by gel electrophoresis and was used for sequencing. Sequenase version 2.0 double-stranded DNA sequencing kit from USB was used as per the manufacturer's instructions.

2.3 Transfection of 293 cells with wild type and mutant EF cDNAs

1×10^5 293 (human embryonic kidney cell line) cells were plated in 60 mm tissue culture plates (Nunc) in DMEM containing 10% bovine calf serum (Hyclone). The cells were transfected with lipofectin (Gibco-BRL) as per the manufacturer's instructions. Transfectants were selected on G-418 (800 µg/ml) for 14 days. The antibiotic resistant clones were picked up and expanded. These clones were screened for expression of EF.

2.4 Northern blotting

Expression of EF in positive clones was confirmed by Northern blotting after initial screening by immunostaining. RNA was extracted from untransfected and transfected 293 cells by Chomczynski and Sacchi (1987) method and run on 1.2% agarose gel containing formaldehyde. It was blotted onto a nitrocellulose membrane (Hybond-C extra, Amersham) and probed with [³²P]-labelled EF cDNA. One positive clone was selected from each of the three transfections (GE1, GE2 and wild type EF) for extraction of recombinant protein.

2.5 Extraction of acid-soluble proteins from transfected cells

Acid-soluble proteins were extracted from untransfected and transfected 293 cells by the standard acid-ethanol procedure used routinely in our laboratory for extraction of EF from mouse intestines (Mulherkar and Deo 1986). Wild type and transfected cells were grown in 10 × 10 cm petri-plates till they attained ~ 80% confluency (~ 1×10^8 cells). Cells were washed thrice with PBS and extracted in HCl and ethanol containing PMSF and Aprotinin as protease inhibitors. The homogenate was extracted overnight at 4°C with constant stirring. After centrifugation at 17,000 g for 30 min at 4°C, the pH of the supernatant was adjusted to 5.2, with 25% ammonium hydroxide. The precipitated proteins were discarded after centrifugation at 17,000 g for 30 min at 4°C. The supernatant was then precipitated with two volumes of chilled absolute ethanol and four volumes of chilled ether, and allowed to stand overnight at -20°C. The precipitate obtained was

air dried and reconstituted in 1 M acetic acid. The acid-soluble proteins were dialysed against 0.1 M acetic acid at 4°C. The dialysate consisting of the crude extract of proteins was lyophilized, washed twice with distilled water and aliquots were stored frozen until further use.

2.6 Immunoblotting

Acid-soluble proteins were separated on a 17.5% SDS-PAGE and transferred to a nitrocellulose membrane (Hybond-C extra). ECL Plus Western blot kit (Amersham) was used according to the manufacturer's instructions. Rabbit polyclonal anti-EF antiserum was used at the dilution of 1 : 5000.

2.7 PLA₂ assay by using labelled Escherichia coli membranes

PLA₂ activity was also checked using [³H]oleic acid labelled *E. coli* (Elsbach and Weiss 1991). For the assay, labelled *E. coli* cells were washed and resuspended in PLA₂ buffer [100 mM Tris (pH8)/10 mM CaCl₂/0.1% BSA] such that 100 µl had ~ 100,000 cpm. Labelled membranes (100 µl substrate) were added to serial dilutions of the acid/ethanol extracted test samples. The reaction was carried out at RT for 1 h after which 250 µl of chilled stop buffer (100 mM EDTA in 1% BSA) was added. Supernatant (400 µl) was collected in a Dioxan based scintillation fluid for counting in the beta counter. The data were plotted as cpm released against concentration of the protein.

2.8 Measurement of enhancing activity

Enhancing activity was measured as described earlier (Mulherkar and Deo 1986) using A431 cells and [¹²⁵I]-EGF. Lyophilized test protein was dissolved in 100 µl of binding buffer and added to the cells with 100 µl of [¹²⁵I]-EGF (counts adjusted to 30,000 cpm/100 µl; specific activity ~ 80 µCi/µg). Non-specific binding was determined in the presence of 50 ng of unlabelled EGF. Cells were lysed in lysis buffer and counted in a gamma counter. The enhancing activity was calculated as the percentage of EGF bound above the control level. Non-specific binding was subtracted from all the readings. Each sample was tested in duplicate and the assay repeated thrice.

2.9 Heparin binding and Western blot analysis

Approximately 75 µg of acid-soluble protein from each of the three clones as well as untransfected 293 cells was mixed with 100 µl of heparin-sepharose beads (Pharmacia), prewashed and suspended in 200 µl of phosphate buffer and incubated overnight at 4°C on a shaker. After incu-

bation, the suspension was centrifuged and the supernatant saved as the unbound protein fraction for Western blotting. The beads were washed with phosphate buffer and the heparin-bound fraction was eluted using 2 M NaCl in the buffer. NaCl-eluted fraction was dialysed using Ultrafree MC tubes (Millipore) and subjected to immunoblotting along with unbound fractions as described earlier.

3. Results

Site-directed mutagenesis reactions were carried out using pRcCMV-EF as template with either GE1 or GE2 as mutant primers. This reaction was used for transformation and the antibiotic resistant colonies were screened for the presence of mutation. In the case of GE1 mutation, colonies were screened by sequencing and one out of six clones sequenced was found to have the GE1 mutation (figure 1a). For GE2 mutation, colonies were screened by restriction digestion as the mutation would result in loss of one of the *Scal* sites; this was later con-




Figure 1. Confirmation of sequence of the mutant EF cDNAs. (a) Panel 1 shows wild type EF sequence as compared to panel 2 showing GE1 mutant sequence from one of the clones (catgac → cagaaa). (b) Plasmid minipreps cut with *Scal* to screen for GE2 mutation. Lane 7 shows the clone with GE2 mutation where one of the *Scal* sites is lost. (c) Panel 1 shows wild type EF sequence compared to panel 2 showing GE2 mutant sequence from one of the clones (ta → aa and gt → ga).

firmed by sequencing (figure 1b, c). Plasmid with GE1 mutation was designated as pRcCMV-GE1 and that with GE2 mutation as pRcCMV-GE2. Both these plasmids, along with pRcCMV-EF (wild type) were used for producing recombinant proteins by transfecting into 293 cells.

G418-resistant clones were picked up and expanded. One clone for each of the three transfections was selected on the basis of positive staining in immunohistochemistry (data not shown). Clone 293/GE1, 293/GE2 and 293/

wtEF produced mutant GE1, mutant GE2 and wild type EF protein respectively. RNA extracted from these clones as well as untransfected 293 cells were subjected to Northern hybridization using radiolabelled EF cDNA. All three transfectants gave a positive signal (figure 2a), which confirmed the expression of mutant EF cDNAs. Western blot analysis of acid-soluble proteins gave a 14 kDa signal in transfectants and not in the untransfected 293 cells, confirming the production of EF protein by each of these clones (figure 2b). Untransfected cells were used as controls.

Acid-soluble proteins from these clones were tested for enhancing and PLA₂ activity. Both the mutants showed loss of enhancing activity (figure 3). Clone 293/GE1 showed complete loss of PLA₂ activity whereas clone 293/GE2 showed partial loss of PLA₂ activity as compared to wild type EF protein (figure 4).

The mutant as well as wild type proteins were also checked for their ability to bind to heparin using heparin-agarose beads. Surprisingly, neither of the mutations resulted in loss of heparin binding (figure 5).

4. Discussion

EF is a 14 kDa molecule isolated from mouse small intestines, identified by its ability to increase the binding of [¹²⁵I]-EGF to A431 cells in the radio-receptor assay (Mulherkar and Deo 1986). Sequence homology studies have shown that EF belongs to mouse type II sPLA₂ family. Hence it is a dual function molecule having enhancing as well as phospholipase activity. Previous studies in our laboratory have shown that both these activities lie in different domains of the EF/sPLA₂ molecule (Kadam




Figure 2. (a) Northern blot analysis. RNA extracted from untransfected 293, 293/wtEF, 293/GE1 and 293/GE2 was Northern blotted and probed with [³²P]-labelled EFcDNA. ~ 0.8 kb signal was obtained in all the three transfectants (top picture shows ethidium bromide gel and bottom picture is the autoradiogram. Arrow indicates 0.8 kb transcript). (b) Western blot analysis. 50 µg acid-soluble proteins from untransfected 293 (lane 1), 293/wtEF (lane 2), 293/GE1 (lane 3), 293/GE2 (lane 4) were separated on 17.5% SDS-PAGE and Western blotted as described in § 2. 14 kDa signal was seen in all the three transfectants (as indicated by arrow). In all cases the positive control (with purified EF) shows a single band.




Figure 3. Enhancing activity of wild type and mutant recombinant EF proteins. Radio-receptor assay was carried out in duplicate wells as described in § 2. Control wells had no protein added to A431 cells. Acid-soluble proteins extracted from 293/wtEF served as positive control and those from untransfected 293 cells served as negative control.




Figure 4. PLA₂ activity of the acid-soluble proteins. Serial dilutions of acid-soluble proteins extracted from the transfectants as well as untransfected 293 cells were taken for the enzyme assay. 293/wtEF served as positive control and untransfected 293 served as negative control.

and Mulherkar 1999). In order to identify residues involved in enhancing activity site-directed mutagenesis was carried out.

Most of the amino acids involved in the catalytic reaction of sPLA₂ are clearly defined (Murakami *et al* 1997). Asp⁴⁹ and a glycine rich sequence Tyr²⁵-Gly-Cys-X-Cys-Gly-X-Gly-Gly-X-X-X-Pro³⁷ form the calcium-binding loop of sPLA_{2s} (Scott *et al* 1990) while His⁴⁸ is the conserved active site residue. A naturally occurring variant of group II sPLA₂ isolated from snake venom, Myotoxin II, shows presence of Lys⁴⁹ instead of Asp⁴⁹ and lacks catalytic activity on conventional substrates (van den Bergh *et al* 1989). Nevertheless, it exerts myotoxic and membrane damaging activities comparable to the Asp⁴⁹ sPLA₂.

Hence Asp⁴⁹ along with His⁴⁸ were selected for substitution by other residues in order to knock off the PLA₂ activity and study the effect on enhancing activity. A specific primer (GE1) was designed to change His⁴⁸ → Gln and Asp⁴⁹ → Lys. A second mutation was made to change some of the tyrosine residues of EF. This was because previous studies from our laboratory indicated that iodination of EF resulted in loss of enhancing activity which could be due to iodination of some of the tyrosine residues. To study the effect of substitution of some of the tyrosine residues on enhancing activity, a primer (GE2) was designed to change Tyr⁶⁷ and Tyr⁶⁹ to Asn⁶⁷ and Asn⁶⁹ respectively.

Mutant proteins were tested for enhancing activity as well as PLA₂ activity. Mutation GE1 [H⁴⁸ → Q and D⁴⁹ → K] which changes amino acids required for Ca²⁺ binding, resulted in loss of PLA₂ activity as expected but




Figure 5. Heparin binding property of mutant proteins. Acid-soluble proteins from 293/wtEF (lanes 1 and 2), 293/GE1 (lanes 3 and 4) and 293/GE2 (lanes 5 and 6) were incubated with heparin-Sepharose beads as described in § 2. The high-salt eluted (lanes 1, 3, 5) and unbound (lanes 2, 4, 6) proteins were separated by SDS-PAGE (17.5%) and Western blotted. 14 kDa signal was seen in the eluted fractions of all the proteins and not the unbound fraction.

it also caused loss of enhancing activity. This confirmed that Ca²⁺ binding is required for both the activities. Hence, though both the activities are independent of each other, Ca²⁺ binding is essential for both of them.

Mutation GE2 [Y⁶⁷ → Q and Y⁶⁹ → Q] resulted in loss of enhancing activity suggesting that these tyrosine residues are important for enhancing activity. Heparin binding analysis showed that neither of the mutations resulted in loss of heparin binding. This indicates that these amino acids do not form part of heparin binding domain. However they could be involved either in binding of EF to cell membrane or to EGF. We have shown before that mouse

sPLA₂/EF has a cell surface receptor that is probably a heparan sulfate proteoglycan (Wagle *et al* 1997). C-terminal lysine residues of type II sPLA₂ have been demonstrated to be involved in binding to heparin as well as cell surface heparan sulfate proteoglycan (Kadam and Mulherkar 1999). Replacement of Lys¹¹⁹ and Lys¹²⁰ reduced the affinity of mouse and rat PLA₂s for heparin and discontinued its binding to the cell surface. But not all the residues for heparin binding and cell surface binding are common (Murakami *et al* 1996). Replacement of Lys¹⁰³ and Lys¹⁰⁴ did not reduce the affinity of sPLA₂ for heparin but did reduce its cell surface binding significantly. Replacement of Tyr⁶⁷ and Tyr⁶⁹ (GE2 mutation) in EF does not affect the heparin binding but it abolishes enhancing activity. Using this mutant molecule it would be possible to study if these tyrosine residues could affect the cell surface binding of EF/mouse sPLA₂. However, whether their substitution caused a conformational change in the molecule remains to be elucidated. We did not measure binding or activity when cells are transfected with the vector alone but do not expect there to be any difference.

GE2 mutation also caused partial loss of PLA₂ activity. Apart from mouse sPLA₂, human and rat type II sPLA₂ show presence of tyrosine at position 67 (Murakami *et al* 1997). Our results demonstrate that Tyr⁶⁹ along with Tyr⁶⁷ is also important for catalytic activity in mouse sPLA₂. Unfortunately we were unable to measure the binding of mutant proteins to A431 cells. Given that neither mutant lost heparin binding activity our data would have been stronger if we could have shown that mutant proteins could bind cells but were inactive. But for reasons that remain unclear, we are unable to label EF protein and retain binding activity.

From these results we can conclude that though enhancing activity and phospholipase activity are two independent activities of the same molecule, there are some amino acids that appear to be common for both activities. His⁴⁸, Asp⁴⁹, Tyr⁶⁷ and Tyr⁶⁹ are the residues, which are important for both these activities.

Acknowledgements

This work was supported by a grant from Council of Scientific and Industrial Research, New Delhi (Grant # 37/985/98-EMR-II). Ms Bhakti Kirtane was recipient of UGC Fellowship. The authors are thankful to Dr (Mrs) Archana Wagle and Ms Shefali Desai for their useful comments during the work as well as during the preparation of manuscript.

References

- Chomczynski P and Sacchi N 1987 Single step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction; *Anal. Biochem.* **162** 156–159
- Deo M G, Mulherkar R and Mane S M 1983 Isolation of a polypeptide that enhances cellular binding of Epidermal Growth Factor; *Indian J. Biochem. Biophys.* **20** 228–231
- Desai S J, Mulherkar R, Wagle A S and Deo M G 1991 Ontogeny of Enhancing Factor in mouse intestines and skin; *Histochemistry* **96** 371–374
- Elsbach P and Weiss J 1991 Utilization of labelled *Escherichia coli* as phospholipase substrate; *Methods Enzymol.* **197** 24–31
- Fonteh A N, Atsumi G, LaPorte T and Chilton F H 2000 Secretory phospholipase A₂ receptor-mediated activation of cytosolic phospholipase A₂ in murine bone marrow-derived mast cells; *J. Immunol.* **165** 2773–2782
- Francis B, Gutierrez J M, Lomonte B and Kaiser I I 1991 Myotoxin II from *Bothrops Asper* (terciopelo) venom is a lysine-49 phospholipase A₂; *Arch. Biochem. Biophys.* **284** 352–359
- Kadam S and Mulherkar R 1999 Enhancing activity and phospholipase activity: two independent activities present in the enhancing factor molecule; *Biochem. J.* **340** 237–243
- Mulherkar R and Deo M G 1986 Further, studies on Enhancing Factor and its possible mechanism of action; *J. Cell Physiol.* **127** 183–188
- Mulherkar R, Desai S J, Rao R S, Wagle A S and Deo M G 1991 Expression of Enhancing Factor gene and its localization in mouse tissues; *Histochemistry* **96** 367–370
- Mulherkar R, Rao R, Rao L, Patki V, Chauhan V S and Deo M G 1993 Enhancing factor protein from mouse small intestines belongs to the phospholipase A₂ family; *FEBS Lett.* **317** 263–266
- Murakami M, Nakatani H, Atsumi G, Inoue K and Kudo I 1997 Regulatory functions of phospholipase A₂; *Crit. Rev. Immunol.* **17** 225–283
- Murakami M, Nakatani Y and Kudo I 1996 Type II secretory phospholipase A₂ associated with cell surfaces via C-terminal heparin-binding lysine residues augments stimulus-initiated delayed prostaglandin generation; *J. Biol. Chem.* **271** 30041–30051
- Scott D L, White S P, Otwinowski Z, Yuan W, Gelb M H and Sigler P B 1990 Interfacial catalysis: the mechanism of phospholipase A₂; *Science* **250** 1541–1546
- Triggiani M, Granata F, Oriente A, De Marino V, Gentile M, Calabrese C, Palumbo C and Marone G 2000 Secretory phospholipases A₂ induce beta-glucuronidase release and IL-6 production from human lung macrophages; *J. Immunol.* **164** 4908–4915
- van den Bergh C J, Slotboom A J, Verheij H M and de Haas G H 1989 The role of Asp-49 and other conserved amino acids in phospholipases A₂ and their importance for enzymatic activity; *J. Cell Biochem.* **39** 379–390
- Wagle A, Patki V, Desai S J and Mulherkar R 1997 Heparin inhibits enhancing factor/phospholipase A₂ activity and its binding to the cell surface; *J. Biosci.* **22** 537–543

MS received 30 April 2002; accepted 22 July 2002

Corresponding editor: VIDYANAND NANJUNDIAH